Skip to main content
Figure 5 | BMC Cancer

Figure 5

From: Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis

Figure 5

KRAS mutant NSCLC specimens express higher activated PAK1 compared to KRAS wild type samples. A-Dot plot demonstrating immunohistochemical expression of p-PAK1(Thr423) in KRAS mutant and KRAS wild type NSCLC clinical specimens. p-PAK1(Thr423) is detectable in all KRAS mutant specimens while most KRAS wild type samples express lower p-PAK1(Thr423). B- Dot plot demonstrating immunohistochemical expression of E-cadherin in KRAS mutant vs. KRAS wild type NSCLC clinical specimens.

Back to article page